Japan's Ministry of Health, Labor and Welfare (MHLW) has granted manufacturing and marketing approval for Andembry ...

CSL Limited (ASX:CSL) shareholders are probably feeling a little disappointed, since its shares fell 4.8% to AU$257 in the ...

CSL Limited (ASX:CSL) shareholders are probably feeling a little disappointed, since its shares fell 4.8% to AU$257 in the week after its latest half-year results. Revenues of US$8.5b were in line ...

Today's Elliott Wave analysis provides an update on the Australian Stock Exchange (ASX) focusing on CSL LIMITED (CSL). There is significant upside potential in the third wave of ASX:CSL. This analysis ...

CSL Vifor Thank you for standing by and welcome to the CSL Limited Half Year Financial Results. All participants are in a listen-only mode. There will be a presentation followed by a question-and ...

This week, the CSL Ltd (ASX: CSL) share price hit a 52-week low. Should investors view the ASX healthcare share as a buy?

There were positives and negatives in the company's first half performance. The post CSL shares push higher despite 'mixed ...

Let's see how this biotech giant performed during the first half of FY 2025. The post CSL share price on watch amid $2.1b ...

The European Commission has granted marketing authorization for Kostaive (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, ...

CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...